Everything below concerns peptide hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-25. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The London and Home Counties Traffic Advisory Committee was established in 1924 to advise the Minister of Transport on issues concerning traffic and transport in the London Traffic Area. It was abolished in 1965. The purpose of the committee, as stated in the Act was "giving advice and assistance in manner provided by this Act to the Minister of Transport... in connection with the exercise and performance of his powers and duties in relation to traffic within the... London Traffic Area..."
The 2021 Copa América, relocated to Brazil at short notice, brought a third-place finish. Colombia beat Ecuador 1–0, drew 0–0 with Venezuela, then lost 2–1 to Peru and 2–1 to Brazil to finish third in Group B on four points. They eliminated Uruguay 4–2 on penalties in the quarter-finals in Brasília, a match in which David Ospina passed Carlos Valderrama's appearance record to become Colombia's most-capped player. Argentina won the semi-final 3–2 on penalties after a 1–1 draw, and Colombia beat Peru 3–2 in the third-place match, Luis Díaz scoring twice to finish as the tournament's joint leading scorer with Lionel Messi on four goals. Qualification for Qatar was lost to a scoring drought spanning seven consecutive matches. Although Colombia beat Venezuela 1–0 in their final fixture, they finished sixth on 23 points, one behind Peru, who took the play-off place. Rueda left shortly afterwards.
The most common reactions of benzene involve substitution of a proton by other groups. Electrophilic aromatic substitution is a general method of derivatizing benzene. Benzene is sufficiently nucleophilic that it undergoes substitution by acylium ions and alkyl carbocations to give substituted derivatives. The most widely practiced example of this reaction is the ethylation of benzene.
Sources: en.wikipedia.org
=== Drug-drug interactions === Lamividine/zidovudine interacts with stavudine and zalcitabine by competing intracellularly for activation and results in inhibiting phosphorylation. There is also a known interaction with nephrotoxic or bone marrow suppressive agents (e.g. doxorubicin) which increases the risk of hematologic toxicity of zidovudine. Monitoring renal function and hematologic tests can be used to assess these potential interactions.
11 August – A bioengineered cornea made from pig's skin is shown to restore vision to blind people. It can be mass-produced and stored for up to two years, unlike donated human corneas that are scarce and must be used within two weeks. 12 August — The National Centers for Environmental Information publish a report, where they state an all-time record cold temperature occurred in Australia during the month. On October 7, 2022, Zack Labe, a climate scientist for the NOAA GFDL releases a statement and a climate report from Berkeley Earth denying the all-time record cold temperature occurred saying, "There are still no areas of record cold so far in 2022." Labe's statement also denies the record cold temperatures in Brazil, reported by the National Institute of Meteorology in May 2022, a month before the official start of winter, was also not record cold temperatures. 13 August – Rocket Lab describes its self-funded plans in detail, first announced in early 2020, to send a probe to Venus, likely in 2023, to search for life in the planet's cloud layer, where other scientists reported the potential detection of biosignature-levels of phosphine in late 2020 and thereafter. ~14 August – As record-breaking heatwaves and droughts affect water supplies, rivers (along with shipping and nuclear reactor cooling), ecosystems, various global supply chains, health, and agriculture worldwide, in Europe, Spain domestically restricts e.g.
Human cells require iron in order to obtain energy as ATP from a multi-step process known as cellular respiration, more specifically from oxidative phosphorylation at the mitochondrial cristae. Iron is present in the iron–sulfur cluster and heme groups of the electron transport chain proteins that generate a proton gradient that allows ATP synthase to synthesize ATP (chemiosmosis). Heme groups are part of hemoglobin, a protein found in red blood cells that serves to transport oxygen from the lungs to other tissues. Heme groups are also present in myoglobin to store and diffuse oxygen in muscle cells.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.